Dennis Helling Net Worth

The estimated Net Worth of Dennis Helling is at least $593 Tisíc dollars as of 4 March 2022. Dennis Helling owns over 5,000 units of Tabula Rasa HealthCare Inc stock worth over $369,096 and over the last 7 years he sold TRHC stock worth over $0. In addition, he makes $223,625 as Independent Director at Tabula Rasa HealthCare Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Dennis Helling TRHC stock SEC Form 4 insiders trading

Dennis has made over 9 trades of the Tabula Rasa HealthCare Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of TRHC stock worth $30,850 on 4 March 2022.

The largest trade he's ever made was buying 7,194 units of Tabula Rasa HealthCare Inc stock on 10 November 2021 worth over $99,709. On average, Dennis trades about 2,360 units every 45 days since 2017. As of 4 March 2022 he still owns at least 35,152 units of Tabula Rasa HealthCare Inc stock.

You can see the complete history of Dennis Helling stock trades at the bottom of the page.

Dennis Helling biography

Dr. Dennis K. Helling serves as Independent Director of the Company. Dr. Helling has been a Clinical Professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences since 1992. From 1992 until January 2013, Dr. Helling served as the Executive Director of Pharmacy Operations and Therapeutics at Kaiser Permanente Colorado, a nonprofit health maintenance organization that develops innovative pharmacy services. In 1979, Dr. Helling co-founded the American College of Clinical Pharmacy, an international association of clinical pharmacists dedicated to optimizing drug therapy outcomes in patients, and served as President from 1997 through 1998. Dr. Helling also served as President of the Accreditation Council for Pharmacy Education, a national agency responsible for the accreditation of professional degree programs in pharmacy, from 2002 through 2004 and the American Pharmacists Association Foundation, a nonprofit organization whose mission is to improve health by inspiring philanthropy, research, and innovation that advances pharmacists’ patient care services, from 2010 through 2012. Over his career, Dr. Helling has been actively involved in hospice and palliative care, serving on the boards of Care Synergy since 2015 and as Vice-Chair of The Denver Hospice Board of Directors since 2009. Dr. Helling has also chaired the Working Group on Pharmacy Reimbursement in the Federation of International Pharmacy. Dr. Helling currently serves on the American Pharmacists Association Board of Trustees and Pharmacy Specialties Board of Directors. Dr. Helling earned a BSPharm from the St. Louis College of Pharmacy, a PharmD from the University of Cincinnati College of Pharmacy and completed his residency at Cincinnati General Hospital. Dr. Helling was awarded the highest national honor in pharmacy, the Remington Honor Medal, in 2013.

What is the salary of Dennis Helling?

As the Independent Director of Tabula Rasa HealthCare Inc, the total compensation of Dennis Helling at Tabula Rasa HealthCare Inc is $223,625. There are 10 executives at Tabula Rasa HealthCare Inc getting paid more, with Calvin Knowlton having the highest compensation of $5,135,730.

How old is Dennis Helling?

Dennis Helling is 71, he's been the Independent Director of Tabula Rasa HealthCare Inc since 2017. There are 1 older and 15 younger executives at Tabula Rasa HealthCare Inc. The oldest executive at Tabula Rasa HealthCare Inc is A. Gordon Tunstall, 76, who is the Lead Independent Director.

What's Dennis Helling's mailing address?

Dennis's mailing address filed with the SEC is 228 STRAWBRIDGE DRIVE, SUITE 100, MOORESTOWN, NJ, 08057.

Insiders trading at Tabula Rasa HealthCare Inc

Over the last 8 years, insiders at Tabula Rasa HealthCare Inc have traded over $245,667,405 worth of Tabula Rasa HealthCare Inc stock and bought 1,486,398 units worth $7,620,320 . The most active insiders traders include Calvin H Knowlton, Orsula V Knowlton a Capital Management, L.P.Ic .... On average, Tabula Rasa HealthCare Inc executives and independent directors trade stock every 8 days with the average trade being worth of $441,116. The most recent stock trade was executed by Michael Greenhalgh on 28 June 2023, trading 25,000 units of TRHC stock currently worth $77,750.

What does Tabula Rasa HealthCare Inc do?

the tabula rasa healthcare family of companies provide new beginnings for our clients, through innovative service models and fresh approaches to healthcare technology. our leaders understand that to maximize patient experiences and outcomes, they must help providers to balance efficiency and scalability with safety and individualization of care.

Complete history of Dennis Helling stock trades at Tabula Rasa HealthCare Inc

Tabula Rasa HealthCare Inc executives and stock owners

Tabula Rasa HealthCare Inc executives and other stock owners filed with the SEC include:

• Calvin Knowlton,
  Chairman of the Board, Chief Executive Officer, Co-Founder
• Orsula Knowlton,
  President, Co-Founder, Chief Marketing Officer & New Business Development Officer, Director
• Brian Adams,
  Chief Financial Officer
• Pamela Schweitzer,
  Independent Director
• Dr. Calvin H. Knowlton BSc Pharm, MDiv, Ph.D.,
  Co-Founder, Chairman & CEO
• A. Gordon Tunstall,
  Lead Independent Director
• Dr. Orsula Voltis Knowlton BScPharm, M.B.A., MBA, Pharm.D., PharmD,
  Co-Founder, Pres, Chief Marketing & New Bus. Devel. Officer and Director
• Michael Greenhalgh,
  Chief Operating Officer
• Michael Purcell,
  Independent Director
• Samira Beckwith,
  Independent Director
• Dennis Helling,
  Independent Director
• Jan Berger,
  Independent Director
• Kathrine O'Brien,
  Independent Director
• Frank Sparacino,
  IR Contact Officer
• Jeffrey DiFrancesco,
  Chief Product Officer
• Bob Sullivan,
  Chief Technology Officer
• Steve Lemak,
  Senior Vice President - IT Infrastructure, CareVention HealthCare Division
• Michael Greenhalgh,
  Co-Founder, Chief Operating Officer
• Frank Sparacino C.F.A., CPA,
  Sr. VP of Investor Relations & Corp. Devel.
• Phillip W. Heath MS,
  Chief Admin. Officer
• Dr. Jacques Turgeon B.Pharm., Ph.D.,
  Chief Scientific Officer & CEO of TRHC Precision Pharmacotherapy, R&D Institute
• Joseph J. Filippoli,
  Chief Information Officer
• Bob Sullivan M.S.,
  Chief Technology Officer
• Andrea Carolan Speers M.S.,
  Corp. Controller & Chief Accounting Officer
• Bruce Luehrs,
  Director
• Venture Partners Iii, Llcra...,
  
• Eric R Arnson,
  10% owner
• Growth Fund 1 Q Lpbressner ...,
  
• Daniel C Lubin,
  Director
• Michael J Gausling,
  10% owner
• Glen R Bressner,
  Director
• Growth Fund 1 A Lpbressner ...,
  
• Joann M. Durham,
  10% owner
• John R. Durham,
  10% owner
• Growth Fund 1 A Lp Originat...,
  
• Stage2 Ventures, L.P.Stage2...,
  
• Growth Fund 1 Q Lp Originat...,
  
• Michael Anthony Bruno,
  CHIEF ACCOUNTING OFFICER
• Ronald Paul Mitchell,
  
• Thomas Cancro,
  CHIEF FINANCIAL OFFICER
• Richard W. Ii Rew,
  CHIEF LEGAL OFFICER, SECRETARY
• Jonathan David Schwartz,
  
• Capital Management, L.P.Ic ...,
  
• Capital Management, L.P.Ic ...,
  
• Capital Management, L.P.Ind...,